The final Clinical Advisory Panel (CAP) meeting for the CD19/22-CAR program was conducted on October 17 2023. We provided the following summary of the project during the CAP presentation. The CD19/22-CAR program successfully met all grant milestones. We observed beneficial clinical outcomes, and response rates were very similar to commercial Tis-cel patients but inferior to commercial Axi-cel for LBCL patients. We observed limited toxicity and the CD19/22-CAR was very well-tolerated in both LBCL and B-cell Acute Lymphocytic Leukemia (B-ALL) patients. Closed system manufacturing using the Miltenyi Prodigy platform was feasible and generated potent products. A significant percentage of ALL subjects relapsed with CD19 negative disease, many with preserved CD22, thus we will re-approach multi-antigen targeting with new constructs and strategies. Given the lack of commercial therapy for Adults with relapsed/refractory disease and the high rate of CD19+ relapse associated with poor persistence in B-ALL, we now propose to test CD19/22 CAR with the goal of enhancing persistence and diminishing CD19+ relapse. In summary, the CD19/22-CAR program has helped Stanford develop GMP laboratory and clinical research expertise and infrastructure that can be broadly applied to future CAR-T programs.